Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Contract Win

24 Jan 2006 07:01

Sopheon PLC24 January 2006 Embargoed: 24 January 2006, 07:00hrs Sopheon Plc ("Sopheon" or the "Company") The Solae Company Chooses Sopheon to Automate Stage-Gate(R) Process and Support Product Portfolio Decision-Making Accolade System Cited for Capacity to Reduce Business Risk Associated withInnovation Sopheon, the international software and services company, announced today thatThe Solae Company has begun deploying Sopheon's Accolade process and productportfolio management system enterprise-wide to enhance its innovation processesand strengthen innovation-related decision-making support. The Solae Company is an alliance between DuPont and Bunge Ltd. It is a globalleader in the research and application of soy-based food ingredients. As partof a plan for enhancing its innovation processes, Solae elected to adoptStage-Gate, the widely used product development methodology. That decision ledto a search for a technology solution that could both automate Stage-Gate andhelp the company more effectively develop and control its product portfolio. The Solae Company chose the Sopheon system after researching a mix of options.Accolade was selected in part because it offered a disciplined process forcapturing, evaluating and managing product and project ideas. Solae also sawvalue in the software's provision of centralized, real-time visibility toproject details and automated "what if" analysis as a way to increase the speedand quality of portfolio decision-making. The company's choice of Accolade wasfurther based on the solution's capacity to integrate with Design for Six Sigma(DFSS) methodologies that are integral to Solae's innovation processes. "Solae has worked hard to earn its reputation for innovation leadership," saidJonathan McIntyre, vice president of research and development at The SolaeCompany. "But true innovation is inherently risky. It involves reaching beyondthe boundaries of what your customers are able to tell you and anticipating whatthey are going to need, sometimes before they even know it. A principal reasonThe Solae Company chose to adopt the Sopheon system is that it brings consistentrigor to our examination of the business risks and opportunities associated witheach project entering our product development pipeline. Sopheon's Accolade is atool that fits into our larger process for risk management, reducing the chanceof investing in products that the market won't value." "Users often point to how Accolade has increased the flow of innovation intotheir developmental pipeline," said Andy Michuda, chief executive officer ofSopheon. "Solae's perspective focuses on the equally important issue ofensuring that the product ideas an organization invests in are those that havethe greatest potential for success. As a proven innovator, they understand thatthe management of new products is all about ability to make the right businessdecisions. Accolade gives users a competitive edge by helping them reduceuncertainty in choosing the product ideas they are going to back with theircritical R&D resources." Sopheon Accolade(R) is a registered trademark of Sopheon plc. Stage-Gate(R) is a registered trademark of the Product Development Institute,Inc. All other trademarks and registered trademarks are the sole property of their respective owners. About The Solae Company The Solae Company is a global innovator in the research and application of soyprotein. It serves food and beverage manufacturers, dietary supplementdevelopers, retailers and consumers in 100 countries worldwide, providing themwith better ingredients for better living. Headquartered in St. Louis, Missouri,the company was formed through an alliance between Bunge Limited (NYSE: BG) andDuPont (NYSE: DD). For more information, please visit www.solae.com. About Sopheon Sopheon (LSE: SPE) is an international provider of software and services thathelp organizations improve the business impact of product development. TheSopheon Accolade(R) product development system automates gate- or phase-basedproduct development processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time-to-market. Sopheon is listed on the AIM Market of the LondonStock Exchange and on the Euronext in the Netherlands. For more information,please visit www.sopheon.com. Press Contacts: Ron Helgeson Bonnie Anderson/Jessica RoeberSopheon Bell Pottinger USA (for Sopheon)Tel.: +1 952 851 7585 Tel.: +1 617 210 4755E-mail: ron.helgeson@sopheon.com E-mail: banderson@bellpottingerusa.com E-mail: jroeber@bellpottingerusa.comAndrew SheaThe Solae Company+1 314 982 1314E-mail: ashea@solae.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Dec 20137:00 amRNSDirector/PDMR Shareholding
5th Dec 20137:00 amRNSCorporate Update
19th Nov 20137:00 amRNSSopheon Delivers Accolade® Release 9.0
7th Nov 20137:00 amRNSInterim Management Statement
11th Sep 20133:00 pmRNSHolding(s) in Company
4th Sep 20133:00 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results
15th Aug 20133:00 pmRNSHolding(s) in Company
29th Jul 20133:00 pmRNSHolding(s) in Company
26th Jul 20137:00 amRNSTrading Update
15th Jul 20134:15 pmRNSHolding(s) in Company
28th Jun 20133:00 pmRNSTotal Voting Rights
27th Jun 20133:00 pmRNSHolding(s) in Company
19th Jun 20133:42 pmRNSHolding(s) in Company
19th Jun 20137:00 amRNSNew capabilities with Accolade(R) 8.3
14th Jun 20132:00 pmRNSContract Win
12th Jun 201312:00 pmRNSResult of AGM & GM
12th Jun 20137:00 amRNSAGM Statement
4th Jun 20137:00 amRNSIssue of Shares
2nd May 20137:00 amRNSInterim Management Statement
21st Mar 20137:00 amRNSPreliminary Results
30th Jan 20137:00 amRNSTrading Update
23rd Jan 20137:00 amRNSLaunch of Accolade 8.2
7th Dec 201211:36 amPRNHolding(s) in Company
8th Nov 20127:00 amPRNInterim Management Statement
1st Oct 20127:00 amRNSHolding(s) in Company
1st Oct 20127:00 amRNSDirectors' Options
24th Sep 20127:00 amRNSMarket Transfer to NYSE Alternext Concluded
23rd Aug 20127:00 amRNSAmendment to Terms of Convertible Loan Stock
23rd Aug 20127:00 amRNSInterim Results
23rd Jul 20127:00 amRNSTrading Update
13th Jun 20123:14 pmRNSResult of AGM
13th Jun 20127:00 amRNSAGM Statement
15th May 20127:00 amRNSAmendment to terms of Convertible Loan Stock
3rd May 20127:00 amRNSInterim Management Statement
25th Apr 20127:00 amRNSLaunch of Accolade 8.0
22nd Mar 20127:00 amRNSPreliminary Results
16th Feb 20127:00 amRNSTop 10 Solution Provider to CGM
31st Jan 20127:00 amRNSTrading Update
23rd Dec 201112:32 pmRNSExtension of GEM Equity Line
23rd Dec 201112:29 pmRNSTrading Update
5th Dec 201112:40 pmRNSHolding(s) in Company
3rd Nov 20117:00 amRNSInterim Management Statement
25th Aug 20117:00 amRNSInterim Results
25th Jul 20117:00 amRNSTrading Statement
23rd Jun 20112:15 pmRNSDirector/PDMR Shareholding
15th Jun 20117:00 amRNSAGM Statement
5th May 20117:00 amRNSInterim Management Statement
24th Mar 20117:00 amRNSPreliminary Results
10th Feb 20117:00 amPRNAppointment of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.